Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Notes
Studies on Neurosteroids XXVI. Fluoxetine-Evoked Changes in Rat Brain and Serum Levels of Neuroactive Androgen, 5α-Androstane-3α,17β-diol
Tatsuya HigashiYukiko NaguraKazutake ShimadaToshimasa Toyo'oka
Author information
JOURNAL FREE ACCESS

2009 Volume 32 Issue 9 Pages 1636-1638

Details
Abstract

It is well known that fluoxetine (Fluox), a selective serotonin reuptake inhibitor, increases the brain content of allopregnanolone (AP), a potent neuroactive steroid that positively modulates the action of γ-aminobutyric acid (GABA) at the GABA type A receptors, but the influence of Fluox on the brain and serum levels of a neuroactive androgen, 5α-androstane-3α,17β-diol (3α,5α-Adiol), is poorly understood. In this study, we examined the Fluox-evoked changes in the 3α,5α-Adiol levels and compared the level changes of 3α,5α-Adiol with those of AP. The brain and serum 3α,5α-Adiol and AP levels were determined using previously developed LC-MS/MS. The ratio of the brain 3α,5α-Adiol to the serum 3α,5α-Adiol concentrations (B/S value) was significantly elevated in the rats intraperitoneally administered Fluox (10 mg/kg). Although the magnitude of the Fluox-evoked level change in 3α,5α-Adiol was much lower than that in AP, this study demonstrated that the 3α,5α-Adiol content is also influenced by Fluox. The most probable cause for the increase in the B/S value by the Fluox treatment is the activation of the 3α-hydroxysteroid dehydrogenase enzyme followed by the promotion of the de novo biosynthesis of 3α,5α-Adiol in the brain.

Content from these authors
© 2009 The Pharmaceutical Society of Japan
Previous article
feedback
Top